Analysis of common FDA enforcement actions against peptide companies — warning letter patterns, common violations, and compliance lessons.
Filed under regulation, written for founder-operator, regulator-compliance, journalist, evidence level regulatory-update.
Not medically reviewed. Last updated 2026-05-03. Nothing here is medical advice.
The FDA regularly issues warning letters to companies marketing unauthorized peptide products. Understanding common violations helps industry participants avoid regulatory pitfalls.
The most common violation. Companies sell peptides with explicit or implied health claims without FDA approval. The FDA considers a product a "drug" if it is intended to treat, cure, prevent, or mitigate disease — regardless of how it is labeled.
Products that fail to include required labeling information, use misleading claims, or lack adequate directions for use.
Products manufactured under conditions that do not meet GMP requirements, or products contaminated with other substances.
Pharmacies that compound copies of commercially available drugs outside of shortage provisions, compound using unauthorized bulk substances, or fail to meet 503A/503B requirements.
The FDA frequently cites website content, blog posts, social media posts, and product descriptions that make drug claims about peptide products.
Companies labeling products "for research use only" while simultaneously marketing them with dosing calculators, injection guides, or health-related content that implies human use.
Customer testimonials describing disease treatment or health improvements are considered drug claims by the FDA.
1. Do not make health claims about unapproved peptide products
2. "Research use only" labeling does not provide legal protection if the product is marketed for human use
3. Customer testimonials about health effects constitute drug claims
4. Consult regulatory counsel before marketing peptide products
This article provides regulatory education and does not constitute legal advice.
More guides: All guides, Safety centre, Peptide library.